RSS   Newsletter   Contact   Advertise with us

FibroGen appoints Suzanne Blaug to board of directors

Christian Fernsby | San Francisco, Ca., USA | June 6, 2019
Suzanne BlaugFibroGen, a biopharmaceutical company, announced the appointment of Suzanne Blaug as an independent director to FibroGen’s board of directors.
Ms. Blaug has more than 30 years of strategic and commercial experience in the biopharmaceutical industry.

She has successfully brought new drugs to market at the global, regional, and local country levels in multiple therapeutic areas including Oncology, Cardiovascular, Immunology, Nephrology, Infectious Diseases, Neurology, and Psychiatry.

Ms. Blaug most recently served as Senior Vice President, Global Marketing and Commercial Development at Amgen Inc. from 2012 to 2018.

From 2004 until 2012, Ms. Blaug was at Johnson and Johnson, where she held several positions including Head of Janssen Alzheimer Immunotherapy, Vice President Strategic Marketing and New Business Development at Janssen Europe, and Area Managing Director UK, Italy, and Greece.

Ms. Blaug started her career at Bristol-Myers Squibb in 1983, where she held numerous marketing, strategic, and general management positions in the U.S., Europe, Australia, and New Zealand.

Ms. Blaug is currently a senior advisor at McKinsey and Company, and she serves on the Healthcare at Kellogg Advisory Council at Northwestern University, as well as the Center for the Business of Healthcare Corporate Advisory Board at the University of North Carolina.

Ms. Blaug received her Bachelor of Science degree from the University of North Carolina at Chapel Hill, and her Master of Business Administration from the Kellogg School of Management at Northwestern University.